Correlation of blood concentration with efficacy and safety of tacrolimus in treatment of myasthenia gravis patients
10.3760/cma.j.issn.1671-7368.2018.05.010
- VernacularTitle:重症肌无力患者他克莫司血药浓度与疗效及安全性分析
- Author:
Di CHEN
1
;
Shifang HOU
;
Ming ZHAO
;
Xuelin SUN
;
Hua ZHANG
;
Liping YANG
Author Information
1. 100730,北京医院药学部药物临床风险与个体化应用评价北京市重点实验室
- Keywords:
Myasthenia gravis;
Tacrolimus;
Drug monitoring;
Adverse drug reaction
- From:
Chinese Journal of General Practitioners
2018;17(5):370-373
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship of blood concentration of tacrolimus with efficacy and safety in treatment of patients with myasthenia gravis.Methods The clinical data of 74 patients with myasthenia gravis admitted in our hospital from January 2013 to December 2015 were analyzed retrospectively.The blood concentrations of tacrolimus were determined by chemiluminescence microparticle immunoassay.Treatment effects were evaluated with clinical relative scoring in China.Results There were 41 men and 33 women in 74 patients with the mean age of (56.7 ± 15.8) years.According to the Osserman classification,there were 7 cases of type Ⅰ,18 cases of type Ⅱ b,27 cases of type Ⅱ a,5 cases of type Ⅲ and 17 cases of type Ⅳ.Forty seven patients underwent thymectomy,including 9 cases of thymoma and 38 cases of hyperplasia.Patients were followed up for (28.1 ± 14.5)days,and the effective rate was 74 ％ (55/74).There was no significant correlation between tacrolimus blood concentration and clinical efficacy.The incidence of adverse reaction of tacrolimus was 22％ (16/74),and the incidence of adverse reactions increased with the increase of blood concentration.Conclusion Tacrolimus is effective in treatment of myasthenia gravis.The correlation of blood concentration of tacrolimus with the clinical efficacy needs to be further studied,but certainly,the monitoring of blood concentration can reduce the incidence of adverse reactions.
